• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.

作者信息

Bomben Riccardo, Rossi Francesca Maria, Vit Filippo, Bittolo Tamara, Zucchetto Antonella, Papotti Robel, Tissino Erika, Pozzo Federico, Degan Massimo, Polesel Jerry, Bulian Pietro, Marasca Roberto, Reda Gianluigi, Laurenti Luca, Olivieri Jacopo, Chiarenza Annalisa, Laureana Roberta, Postorino Massimiliano, Del Principe Maria Ilaria, Cuneo Antonio, Gentile Massimo, Morabito Fortunato, Fronza Gilberto, Tafuri Agostino, Zaja Francesco, Foà Robin, Di Raimondo Francesco, Del Poeta Giovanni, Gattei Valter

机构信息

Clinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.

International PhD School in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.

出版信息

Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18.

DOI:
10.1038/s41375-023-01845-9
PMID:36807650
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10079531/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c08/10079531/6f38e84cb3c4/41375_2023_1845_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c08/10079531/6f38e84cb3c4/41375_2023_1845_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0c08/10079531/6f38e84cb3c4/41375_2023_1845_Fig1_HTML.jpg

相似文献

1
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.TP53 缺失对接受依鲁替尼治疗的慢性淋巴细胞白血病患者的临床影响：一项校园慢性淋巴细胞白血病研究
Leukemia. 2023 Apr;37(4):914-918. doi: 10.1038/s41375-023-01845-9. Epub 2023 Feb 18.
2
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study.100例未经治疗的TP53基因缺失慢性淋巴细胞白血病患者接受依鲁替尼持续治疗：一项真实世界的校园慢性淋巴细胞白血病研究。
Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21.
3
Clinical Outcomes in Patients with Multi-Hit Chronic Lymphocytic Leukemia Treated with Ibrutinib.伊布替尼治疗多打击慢性淋巴细胞白血病患者的临床结局。
Clin Cancer Res. 2021 Aug 15;27(16):4531-4538. doi: 10.1158/1078-0432.CCR-20-4890. Epub 2021 May 7.
4
Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.依鲁替尼诱导慢性淋巴细胞白血病细胞凋亡的细胞内在决定因素
Clin Cancer Res. 2017 Feb 15;23(4):1049-1059. doi: 10.1158/1078-0432.CCR-15-2921. Epub 2016 Aug 17.
5
Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations.依鲁替尼可使初治的慢性淋巴细胞白血病（CLL）且伴有17p缺失和/或TP53突变的患者获得持久缓解。
Blood. 2021 Dec 16;138(24):2589-2592. doi: 10.1182/blood.2021012315.
6
The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.在常规临床实践中，伊布替尼剂量调整和临时中断对慢性淋巴细胞白血病患者结局的影响。
Cancer Med. 2020 May;9(10):3390-3399. doi: 10.1002/cam4.2998. Epub 2020 Mar 18.
7
Long-term efficacy of first-line ibrutinib treatment for chronic lymphocytic leukaemia in patients with TP53 aberrations: a pooled analysis from four clinical trials.伴有 TP53 异常的慢性淋巴细胞白血病患者一线伊布替尼治疗的长期疗效：四项临床试验的汇总分析。
Br J Haematol. 2022 Feb;196(4):947-953. doi: 10.1111/bjh.17984. Epub 2021 Dec 5.
8
Disruption in Chronic Lymphocytic Leukemia Under Ibrutinib: More is Worse?伊布替尼治疗下慢性淋巴细胞白血病的疾病进展：越多越糟？
Clin Cancer Res. 2021 Aug 15;27(16):4462-4464. doi: 10.1158/1078-0432.CCR-21-1750. Epub 2021 Jun 14.
9
Predictive significance of selected gene mutations in relapsed and refractory chronic lymphocytic leukemia patients treated with ibrutinib.伊布替尼治疗复发/难治性慢性淋巴细胞白血病患者中选择基因突变的预测意义。
Eur J Haematol. 2021 Mar;106(3):320-326. doi: 10.1111/ejh.13550. Epub 2020 Dec 19.
10
Treatment with ibrutinib does not induce a clonal evolution in chronic lymphocytic leukemia.依鲁替尼治疗不会在慢性淋巴细胞白血病中诱导克隆进化。
Haematologica. 2022 Jan 1;107(1):334-337. doi: 10.3324/haematol.2020.263715.

引用本文的文献

1
Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States.美国慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者真实世界治疗顺序相关的总生存期
Cancers (Basel). 2025 Aug 7;17(15):2592. doi: 10.3390/cancers17152592.
2
The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations.p53突变在对有丝分裂异常的早期和晚期反应中的作用。
Biomolecules. 2025 Feb 8;15(2):244. doi: 10.3390/biom15020244.
3
Deletion of 17p in cancers: Guilt by (p53) association.癌症中17号染色体短臂缺失：因（p53）关联而获罪。

本文引用的文献

1
TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: A retrospective analysis.TP53 改变的慢性淋巴细胞白血病经一线布鲁顿酪氨酸激酶抑制剂为基础的治疗：一项回顾性分析。
Am J Hematol. 2022 Aug;97(8):1005-1012. doi: 10.1002/ajh.26595. Epub 2022 May 30.
2
A clinical practice comparison of patients with chronic lymphocytic leukemia with and without deletion 17p receiving first-line treatment with ibrutinib.伴有和不伴有 17p 缺失的慢性淋巴细胞白血病患者接受伊布替尼一线治疗的临床实践比较。
Haematologica. 2022 Nov 1;107(11):2630-2640. doi: 10.3324/haematol.2021.280376.
3
Oncogene. 2025 Mar;44(10):637-651. doi: 10.1038/s41388-025-03300-8. Epub 2025 Feb 18.
4
Detection of clinically relevant variants in the gene below 10% allelic frequency: A multicenter study by ERIC, the European Research Initiative on CLL.低于10%等位基因频率的基因中临床相关变异的检测：欧洲慢性淋巴细胞白血病研究倡议（ERIC）的一项多中心研究
Hemasphere. 2025 Jan 20;9(1):e70065. doi: 10.1002/hem3.70065. eCollection 2025 Jan.
5
Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.慢性淋巴细胞白血病中基因畸变与信号通路相互作用的见解：从发病机制到治疗策略
Biomark Res. 2024 Dec 28;12(1):162. doi: 10.1186/s40364-024-00710-w.
6
CD49d expression is included in a revised 4-factor model predicting outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: A multicenter real-world experience.CD49d表达被纳入一个经过修订的四因素模型，该模型可预测接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后：一项多中心真实世界研究。
Hemasphere. 2024 Jul 15;8(7):e128. doi: 10.1002/hem3.128. eCollection 2024 Jul.
7
Non-Coding RNAs of Mitochondrial Origin: Roles in Cell Division and Implications in Cancer.线粒体来源的非编码 RNA：在细胞分裂中的作用及其在癌症中的意义。
Int J Mol Sci. 2024 Jul 8;25(13):7498. doi: 10.3390/ijms25137498.
8
Low Cell Bioenergetic Metabolism Characterizes Chronic Lymphocytic Leukemia Patients with Unfavorable Genetic Factors and with a Better Response to BTK Inhibition.低细胞生物能量代谢是具有不良遗传因素且对BTK抑制反应较好的慢性淋巴细胞白血病患者的特征。
Curr Issues Mol Biol. 2024 May 22;46(6):5085-5099. doi: 10.3390/cimb46060305.
9
Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.伊布替尼耐药慢性淋巴细胞白血病中克隆内增殖亚群的早期再现。
Leukemia. 2024 Aug;38(8):1712-1721. doi: 10.1038/s41375-024-02301-y. Epub 2024 Jun 24.
10
ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.ERIC 建议对慢性淋巴细胞白血病中的 TP53 基因突变进行分析-2024 更新。
Leukemia. 2024 Jul;38(7):1455-1468. doi: 10.1038/s41375-024-02267-x. Epub 2024 May 16.
Treatment with ibrutinib does not induce a clonal evolution in chronic lymphocytic leukemia.
依鲁替尼治疗不会在慢性淋巴细胞白血病中诱导克隆进化。
Haematologica. 2022 Jan 1;107(1):334-337. doi: 10.3324/haematol.2020.263715.
4
The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib.伊布替尼治疗的 CLL 患者中核型复杂性和演变对生存的影响。
Blood. 2021 Dec 9;138(23):2372-2382. doi: 10.1182/blood.2020010536.
5
Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia.低变异等位基因频率的突变预示慢性淋巴细胞白血病患者生存期短。
Clin Cancer Res. 2021 Oct 15;27(20):5566-5575. doi: 10.1158/1078-0432.CCR-21-0701. Epub 2021 Jul 20.
6
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases.TP53基因缺失作为靶向治疗时代的一个风险因素：一项对525例慢性淋巴细胞白血病病例的多中心回顾性研究。
Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.
7
Clinical Outcomes in Patients with Multi-Hit Chronic Lymphocytic Leukemia Treated with Ibrutinib.伊布替尼治疗多打击慢性淋巴细胞白血病患者的临床结局。
Clin Cancer Res. 2021 Aug 15;27(16):4531-4538. doi: 10.1158/1078-0432.CCR-20-4890. Epub 2021 May 7.
8
Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options.CLL 中低负担 TP53 突变：不同治疗选择背景下的临床影响和克隆进化。
Blood. 2021 Dec 23;138(25):2670-2685. doi: 10.1182/blood.2020009530.
9
Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model.伊布替尼治疗的慢性淋巴细胞白血病患者预后的预测：建立并验证一个四因素预后模型。
J Clin Oncol. 2021 Feb 20;39(6):576-585. doi: 10.1200/JCO.20.00979. Epub 2020 Oct 7.
10
aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics.慢性淋巴细胞白血病的畸变：诊断改进的临床意义概述。
Haematologica. 2018 Dec;103(12):1956-1968. doi: 10.3324/haematol.2018.187583. Epub 2018 Nov 15.